Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.
Ramtohul T, Lepagney V, Bonneau C, Jin M, Menet E, Sauge J, Laas E, Romano E, Bello-Roufai D, Mechta-Grigoriou F, Vincent Salomon A, Bidard FC, Langer A, Malhaire C, Cabel L, Brisse HJ, Tardivon A.
Ramtohul T, et al. Among authors: langer a.
Radiology. 2024 Sep;312(3):e240575. doi: 10.1148/radiol.240575.
Radiology. 2024.
PMID: 39225608